Evidence map›Paper›PMID 29587397›Full record

ArticleViruses2018

Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin.

Nastasja C Hauck, Josiane Kirpach, Christina Kiefer, Sophie Farinelle, Sophie Maucourant, Stephen A Morris, William Rosenberg, Feng Q He, Claude P Muller, I-Na Lu

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Nastasja C HauckDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. Nastasja.Hauck@gmx.de.
Josiane KirpachDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. josiane.kirpach@lih.lu.
Christina KieferDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. muesli.chrissy.kiefer@googlemail.com.
Sophie FarinelleDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. sophie.farinelle@lih.lu.
Sophie MaucourantiQur Ltd., London NW1 0NH, UK. sophie.maucourant@touchlight.com.ORCID 0000-0001-6272-3210
Stephen A MorrisiQur Ltd., London NW1 0NH, UK. stephen.morris@ucl.ac.uk.
William RosenbergiQur Ltd., London NW1 0NH, UK. william.rosenberg@iqur.com.ORCID 0000-0002-2732-2304
Feng Q HeDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. feng.he@lih.lu.ORCID 0000-0003-2657-7361
Claude P MullerDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. Claude.Muller@lih.lu.
I-Na LuDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. i-na.lu@clin.au.dk.
Luxembourg Institute of Health · LUiQur (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To overcome yearly efforts and costs for the production of seasonal influenza vaccines, new approaches for the induction of broadly protective and long-lasting immune responses have been developed in the past decade. To warrant safety and efficacy of the emerging crossreactive vaccine candidates, it is critical to understand the evolution of influenza viruses in response to these new immune pressures. Here we applied unique molecular identifiers in next generation sequencing to analyze the evolution of influenza quasispecies under in vivo antibody pressure targeting the hemagglutinin (HA) long alpha helix (LAH). Our vaccine targeting LAH of hemagglutinin elicited significant seroconversion and protection against homologous and heterologous influenza virus strains in mice. The vaccine not only significantly reduced lung viral titers, but also induced a well-known bottleneck effect by decreasing virus diversity. In contrast to the classical bottleneck effect, here we showed a significant increase in the frequency of viruses with amino acid sequences identical to that of vaccine targeting LAH domain. No escape mutant emerged after vaccination. These results not only support the potential of a universal influenza vaccine targeting the conserved LAH domains, but also clearly demonstrate that the well-established bottleneck effect on viral quasispecies evolution does not necessarily generate escape mutants.

Indexed as

Evolution, MolecularQuasispeciesAmino Acid SequenceAnimalsAntibodies, ViralCross ReactionsEpitopesFemaleHemagglutinin Glycoproteins, Influenza VirusHigh-Throughput Nucleotide SequencingImmunizationInfluenza A virusInfluenza VaccinesMiceMutationOrthomyxoviridae InfectionsAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesbottleneck effectimmune pressureimmune selectioninfluenzanext generation sequencingunique molecular identifiersvaccinevirus evolution

Identifiers

PMID29587397
PMCPMC5923442
OpenAlexW2790798048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.